sirdalud tablett
sandoz pharmaceuticals d.d. - tisanidiin - tablett - 2mg 30tk
sirdalud tablett
sandoz pharmaceuticals d.d. - tisanidiin - tablett - 4mg 30tk
sirdalud tablett
ideal trade links uab - tisanidiin - tablett - 4mg 30tk
sirdalud tablett
ideal trade links uab - tisanidiin - tablett - 2mg 100tk; 2mg 30tk
sirdalud tablett
ideal trade links uab - tisanidiin - tablett - 4mg 30tk; 4mg 100tk
sirdalud tablett
ideal trade links uab - tisanidiin - tablett - 2mg 30tk; 2mg 100tk
namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic häired - südame teraapia - namuscla on näidustatud sümptomaatiline ravi myotonia täiskasvanud patsientidel, kellel on mitte-huumustoiteline myotonic häired.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.